Hansoh's HS-20093 Meets Primary Endpoint in Phase 3 ARTEMIS-011 in Relapsed or Refractory Osteosarcoma, Cutting Risk of Progression or Death by 67%

HS-20093, independently developed by Hansoh Pharmaceutical, met its primary endpoint in the Phase 3 ARTEMIS-011 study in osteosarcoma, reducing the risk of disease progression or death by 67% versus gemcitabine plus docetaxel. The study enrolled 122 patients whose disease had progressed or relapsed after at least two prior lines of systemic therapy, with a median follow-up of 7.1 months. By BICR assessment, median PFS was 5.5 months with HS-20093 versus 1.4 months with chemotherapy, HR 0.33 (95% CI 0.20–0.55, P<0.0001).